- Home
- GHRS vs PHAR Comparison
GHRS vs PHAR Comparison
Compare GHRS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- PHAR
- Stock Information
- Founded
- GHRS 2018
- PHAR 1988
- Country
- GHRS Ireland
- PHAR Netherlands
- Employees
- GHRS N/A
- PHAR N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- GHRS Health Care
- PHAR Health Care
- Exchange
- GHRS Nasdaq
- PHAR Nasdaq
- Market Cap
- GHRS 892.0M
- PHAR 951.7M
- IPO Year
- GHRS 2021
- PHAR N/A
- Fundamental
- Price
- GHRS $14.38
- PHAR $17.00
- Analyst Decision
- GHRS Strong Buy
- PHAR Strong Buy
- Analyst Count
- GHRS 9
- PHAR 3
- Target Price
- GHRS $30.11
- PHAR $30.00
- AVG Volume (30 Days)
- GHRS 407.8K
- PHAR 19.9K
- Earning Date
- GHRS 11-06-2025
- PHAR 11-06-2025
- Dividend Yield
- GHRS N/A
- PHAR N/A
- EPS Growth
- GHRS N/A
- PHAR N/A
- EPS
- GHRS N/A
- PHAR 0.00
- Revenue
- GHRS N/A
- PHAR $362,274,000.00
- Revenue This Year
- GHRS N/A
- PHAR $17.70
- Revenue Next Year
- GHRS N/A
- PHAR $12.25
- P/E Ratio
- GHRS N/A
- PHAR $3,023.75
- Revenue Growth
- GHRS N/A
- PHAR 26.78
- 52 Week Low
- GHRS $6.72
- PHAR $7.35
- 52 Week High
- GHRS $20.50
- PHAR $17.76
- Technical
- Relative Strength Index (RSI)
- GHRS 55.96
- PHAR 60.61
- Support Level
- GHRS $13.71
- PHAR $15.81
- Resistance Level
- GHRS $15.01
- PHAR $16.83
- Average True Range (ATR)
- GHRS 0.98
- PHAR 0.91
- MACD
- GHRS 0.04
- PHAR 0.09
- Stochastic Oscillator
- GHRS 74.17
- PHAR 86.34
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.